摘要 |
<p>The invention relates to compounds for the treatment of ocular dryness caused by photorefractive surgery. Agents which block the electric activity of injured nerve endings of the neuroma can be used for the treatment of ocular dryness caused by photorefractive surgery, such as excimer laser photorefractive keractomy or laser-assisted in-situ keratomileusis. The administration of said blocking agents effectively reduces the sensations of ocular dryness, said agents including antiepileptics, anticonvulsants, antiarrhythmics, tricyclic antidepressants and local anaesthetics and, in particular, licodaine, tocainidine, phenytoin, carbamazepine, lamotrigine, mexiletine and pregabaline.</p> |